Lamdagen

The figure charts SARS-CoV-2 viral loads in patients in hospital settings across several world regions. Three studies included limited numbers of hospitalized patients with mild to moderate symptoms, while a fourth used a larger sample across a hospital network.

The brief describes the optical properties of LamdaGen’s gold plasmonic sensor surfaces and compares them with those of gold (Au) colloids.

LamdaGen Corporation and Arisan Therapeutics were awarded a $2 million Phase II SBIR grant from the National Institute of Allergy and Infectious Diseases to develop a high-sensitivity point-of-care dual system.

LamdaGen Corporation announced that the European Patent Office granted its application, “Digital LSPR for Enhanced Assay Sensitivity,” for point-of-care diagnostic testing.

LamdaGen Corporation announced that the United States Patent and Trademark Office issued a Notice of Allowance for its patent application, “Digital LSPR for Enhanced Assay Sensitivity.”

LamdaGen Corporation announced that the Japanese Patent Office issued a Notice of Allowance for its application, “Mobile/Wearable Devices Incorporating LSPR Sensors,” for point-of-care diagnostic testing.

No positions are currently available.

LamdaGen Corporation develops and integrates plasmonic biosensors for detection applications, focusing on rapid point-of-use diagnostic systems that require sensitivity and precise quantitation.

LamdaGen lists phone and email contact details and identifies its corporate headquarters and labs as being in Menlo Park, California.

LamdaGen provides biodetection solutions in advanced plasmonics.

LamdaGen Corp. owns the information collected on its site and uses information provided by email or direct contact to respond to inquiries.